Prothena (PRTA) delivered earnings and revenue surprises of -3.13% and 11.43%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 1天前
Prothena Reports Second Quarter 2020 Financial Results and Provides R&D Update
* Net cash used in operating and investing activities was $18.7 million in the second quarter and $41.9 million for the first six months of 2020; quarter-end cash and restricted cash position of $336.6 million provides funding to advance a broad pipeline DUBL
GlobeNewswire · 2天前
Prothena Announces Phase 2 PASADENA Study Results to be Presented at International Congress of Parkinson’s Disease and Movement Disorders
* Phase 2 PASADENA Part 1 study results selected as an oral Top AbstractDUBLIN, Ireland, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of invest
GlobeNewswire · 3天前
Were Hedge Funds Right About Selling Prothena Corporation plc (PRTA)?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds
Insider Monkey · 5天前
Prothena to Report Second Quarter 2020 Financial Results on August 6
DUBLIN, Ireland, July 30, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeleine of investigational therapeutics for neurodegenerative and rare peripheral amyloi
GlobeNewswire · 07/30 20:05
Analysts Estimate Prothena (PRTA) to Report a Decline in Earnings: What to Look Out for
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/28 16:33
Prothena (PRTA) Looks Good: Stock Adds 10.6% in Session
Prothena Corporation Public Limited Company是一家全球生物技术公司。该公司致力于治疗涉及蛋白质错误折叠或细胞粘附疾病的免疫疗法的发现、开发与商业化。该公司的一系列基于抗体的临床候选产品治疗一系列适应症，包括淀粉样蛋白轻链（AL）淀粉样变性病（NEOD001）、帕金森病和其他相关的突触核蛋白病（PRX002），以及炎症性疾病，如银屑病（PRX003）。该公司已经研发选择性结合转淀粉样变（病变）形式甲状腺素蛋白（TTR）介导的淀粉样变性（ATTR）蛋白的单克隆抗体。该公司的产品还包括其测试抗体在淀粉样蛋白或细胞粘附相关疾病的临床前模型中功效的后期发现阶段项目。NEOD001是一种针对在AL淀粉样变性中积累的淀粉样蛋白的单克隆抗体。